Treatment with pyrotinib and the chemotherapies trastuzumab, docetaxel and carboplatin significantly improved response rates over the triplet chemotherapy regimen alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.
Shari Mycek
Advertisement
Articles by Shari Mycek
Advertisement
Latest Updated Articles
Novel 4-Drug Combo Significantly Improves Treatment Responses in Group of Patients with Breast CancerPublished: June 15th 2021 | Updated:
Advertisement
Advertisement
Trending on CURE
1
A Survivor's 30-Year Wait for Lymphedema Relief Ends with Hackensack's New Supermicrosurgery Robotic Procedure
2
FDA Grants Orphan Drug Designation to MNV-201 for Myelodysplastic Syndrome
3
Jakafi Trial Shows Benefits for Patients with Myelofibrosis and Anemia
4
What Breast Cancer Awareness Means to Me as a 23-Year Survivor
5
